COMMUNIQUÉS West-GlobeNewswire

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
07/05/2025
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of [...]
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
07/05/2025
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – [...]
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results
07/05/2025
REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an [...]
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
07/05/2025
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and [...]
Anika to Participate in the Sidoti Virtual Investor Conference
07/05/2025
BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention [...]
Pramana Pharmaceuticals Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline
07/05/2025
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical company developing a transformative small molecule platform targeting the intersection of [...]
Updated full-year outlook for 2025 as a result of DTK closing, market conditions and M&A integration projects
07/05/2025
Company announcement no. 07 – 25 7 May 2025 Updated full-year outlook for 2025 as a result of DTK closing, market conditions and M&A integration projects NTG has completed the acquisition of DTK On 7 May 2025, we [...]
Virbac : Déclaration d'actions et de droits de vote 04/2025
07/05/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 04/2025
07/05/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Scenic Biotech Announces Nature Publication on the Discovery of Drug Target PLA2G15, a Modifier in Lysosomal Disease
07/05/2025
In collaboration with a Stanford University research team, Scenic Biotech identified and characterized PLA2G15 as a novel target in lysosomal storage diseases Amsterdam, the Netherlands, May 07, 2025 – Scenic Biotech , [...]
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
07/05/2025
Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy 66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global [...]
Continued growth in revenue and operating profit
07/05/2025
Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9 million in the year- [...]
Le ministre de l'Éducation annonce que la formation en RCR, DEA et en intervention en cas de surdose d'opioïdes sera désormais obligatoire dans le programme scolaire provincial
07/05/2025
Des élèves de l’Île-du-Prince-Édouard apprennent maintenant à sauver des vies CHARLOTTETOWN, Île-du-Prince-Édouard, 07 mai 2025 (GLOBE NEWSWIRE) -- La Fondation Advanced Coronary Treatment (ACT) s’est jointe au [...]
Minister of Education announces CPR, AED, and Opioid Overdose Response Training now mandatory part of the provincial curriculum
07/05/2025
Prince Edward Island students now learning how to save lives CHARLOTTETOWN, Prince Edward Island, May 07, 2025 (GLOBE NEWSWIRE) -- The Advanced Coronary Treatment (ACT) Foundation joined the Government of Prince Edward [...]
Valneva fait un point suite à l'annonce de l'agence européenne des médicaments sur l'utilisation d'IXCHIQ® chez les personnes âgées
07/05/2025
Saint Herblain (France), le 07 mai 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) a entamé une revue [...]
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
07/05/2025
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose [...]
Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
07/05/2025
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 7 May 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company [...]
VALNEVA Déclaration d’actions et de droits de vote : 30 avril 2025
07/05/2025
VALNEVA Déclaration d’actions et de droits de vote 30 avril 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 rue [...]
VALNEVA Declaration of shares and voting rights: April 30, 2025
07/05/2025
VALNEVA Declaration of shares and voting rights April 30, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]

Pages